Analysis and Prospect of Domestic and Foreign Plague Antibacterial Treatment Plan

doi:10.19803/j.1672-8629.2020.01.01

Abstract

Abstract: Plague is a kind of natural epidemic infectious disease with rapid transmissions, acute onsets, strong infectivity and high fatality rates. There are many plague natural foci in the world, and various biotypes and ecotypes of Yersinia pestis strains as well.In recent years, plague has been reemerging, and there has been a rising trend in many places especially in Africa. China, the United States and other countries are reporting sporadic plague cases. At present, among the differences between domestic and foreign guidelines for the antibacterial treatment of plague, the dosage of streptomycin is the most controversial one. In order to guide medical staff to formulate individualized antibacterial treatment strategy when dealing with different plague foci, biotypes strains and clinical types, this paper compares and analyzes domestic and foreign guidelines and literatures about the antibacterial treatment of plague, and discusses the antibacterial strategies of plague, so as to provide references for future treatments and related researches.

Key words: plague, yersina pestis, antibacterial treatment, guidelines, streptomycin, drug combination.

CLC Number:

R978

CHEN Chong, GE Ziruo, WANG Lin, CHEN Zhihai. Analysis and Prospect of Domestic and Foreign Plague Antibacterial Treatment Plan[J]. Chinese Journal of Pharmacovigilance, 2020, 17(1): 1-5.

References

[1] Welch T J, Florian F W, Mcdermott P F, et al.Multiple Antimicrobial Resistance in Plague: An Emerging Public Health Risk[J]. PLoS ONE, 2007, 2(3):e309.
[2] Fenollar F, Mediannikov O.Emerging infectious diseases in Africa in the 21st century[J]. New Microbes and New Infections, 2018,26:S10-S18.
[3] Bonds M H, Ouenzar M A, Garchitorena A, et al.Madagascar can build stronger health systems to fight plague and prevent the next epidemic[J]. PLoS Negl Trop Dis, 2018,12(1):e6131.
[4] Zeppelini C G, DE Almeida A, Cordeiro-Estrela P.Ongoing quiescence in the Borborema Plateau Plague focus (Paraiba, Brazil)[J]. An Acad Bras Cienc, 2018,90(3):3007-3015.
[5] WHO.Global distribution of natural plague foci as of March2016 [EB/OL].(2019-11-13)(2017-10-31)[2019-11-18]https://wwwwho.int/zh/newsroom/factsheets/detail/plague.html.
[6] CDC.Maps and Statistics [EB/OL].[2019-11-25] https://www. cdc.gov/plague/maps/index.html.
[7] 李硕, 张云辉, 王永怡, 等. 2017年全球传染病热点回顾[J].传染病信息, 2018,31(1):5-10.
[8] 内蒙古锡林郭勒盟卫生健康委、北京市朝阳区卫生健康委.锡林郭勒盟确诊两例鼠疫病例[EB/OL]. (2019-11-13)[2019-11-18]. http://www.chinacdc.cn/jkzt/crb/jl/sy/gzdt/201911/t20191118_206911.html.
[9] 内蒙古自治区卫生健康委员会.锡林郭勒盟一病人在化德县被确诊为腺鼠疫自治区采取切实措施加大防控力度[EB/OL].(2019-11-17)[2019-11-18].http://www.chinacdc.cn/jkzt/crb/jl/sy/gzdt/201911/t20191118_206913.html
[10] 内蒙古自治区卫生健康委员会.内蒙古自治区四子王旗确诊1例腺鼠疫病例[EB/OL]. (2019-11-28)[2019-12-28].http://www.chinacdc. cn/jkzt/crb/jl/sy/gzdt/201911/t20191128_207187.html.
[11] Mehand MS, Millett P, Al-Shorbaji F, et al.World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development[J].Emerg Infect Dis. 2018;24(9):e171427.
[12] Runfola J K, House J, Miller L, et al.Outbreak of Human Pneumonic Plague with Dog-to-Human and Possible Human-to-Human Transmission-Colorado, June-July 2014[J]. MMWR Morb Mortal Wkly Rep, 2015,64(16):429-434.
[13] Welch T J, Fricke W F, McDermott P F, et al. Multiple antimic-robial resistance in plague: an emerging public health risk[J]. PloS one, 2007,2(3):e309.
[14] Wong J D, Barash J R, Sandfort R F, et al.Susceptibilities of Yersinia pestis Strains to 12 Antimicrobial Agents[J]. Anti-microbial Agents and Chemotherapy, 2000, 44(7):1995-1996.
[15] Poland J D, Dennis D T, et al.Plague manual-epidemiology, distribution, surveillance and control[J]. Wkly Epidemiol Rec, 1999, 74(51-52):447.
[16] 应急办.关于印发《鼠疫诊疗方案(试行)》的通知 [EB/OL] . [2011-01-28].http://www.nhc.gov.cn/ html.
[17] CDC. Diagnosis and Treatment [EB/OL] .[2018-11-17] .https:// www. cdc. gov/ plague/ healthcare/ clinicians. html.
[18] Bossi P, Tegnell A, Baka A, et al.Bichat guidelines for the clinical management of plague and bioterrorism-related plague[J]. Euro Surveill,2004,9(12):E5-E6.
[19] 龚正达, 于心, 刘起勇, 等. 中国鼠疫自然疫源地分型研究Ⅵ.鼠疫媒介生物学特征[J]. 中华流行病学杂志, 2012, 33(8):818-822.
[20] Parkhill J, Wren B W, Thomson N R, et al.Genome sequence of Yersinia pestis, the causative agent of plague[J]. Nature, 2001, 413(6855):523-527.
[21] 李琪, 匡扶, 刘春漪, 等. 低氧高碳酸环境对大鼠肺炎模型中左氧氟沙星分布的影响[J]. 中国药业,2019,28(1):9-13.
[22] 邵涛, 秦一, 徐平湘, 等. 低氧与常氧状态下罗红霉素在大鼠体内的药代动力学比较[J]. 中国药理学通报, 2016, 32(11):1596-1601.
[23] Chen L, Gao Z.Continuous hypoxia reduces the concentration of streptomycin in the blood[J]. BMC Infect Dis, 2018,18(1):120.
[24] 唐新元, 王梅, 田富彰, 等. 链霉素单独和联合环丙沙星治疗鼠疫的疗效比较[J]. 中国媒介生物学及控制杂志, 2015,26(3):317-319.
[25] 仁青卓玛, 熊浩明, 魏柏青, 等. 环丙沙星与链霉素联合用药治疗鼠疫患者结果分析[J]. 临床医药文献电子杂志, 2017,4(54):10631, 10634.
[26] 李海龙, 王国钧, 马英. 联合用药治疗3例重症肺鼠疫患者[J]. 中国人兽共患病学报, 2008,24(12):1178-1181.
[27] 何建, 杨晓艳, 李胜, 等. 西藏自治区鼠疫自然疫源地鼠疫耶尔森菌耐药及耐消毒剂基因的研究[J]. 中国媒介生物学及控制杂志, 2018,29(1):61-63.
[28] 张琪, 李胜, 杨晓艳, 等. 青海省海南州鼠疫自然疫源地鼠疫菌病原学及耐药、耐消毒剂基因特征分析[J].中华地方病学杂志, 2018,37(9):702-706.
[29] 李胜, 杨晓艳, 何建, 等. 青海省海西州鼠疫自然疫源地鼠疫菌病原学及耐药、耐消毒剂基因特征分析[J].中华地方病学杂志2019, 38(1):15-20.
[30] 靳娟, 何建, 杨晓艳, 等. 玉树州鼠疫自然疫源地鼠疫菌耐药及耐消毒剂相关基因的检测[J]. 中国卫生检验杂志, 2018,28(11):1285-1287.
[31] Urich S K, Chalcraft L, Schriefer M E, et al.Lack of Antimicrobial Resistance in Yersinia pestis Isolates from 17 Countries in the Americas, Africa, and Asia[J]. Antimicrobial Agents and Chemotherapy, 2012,56(1):555-558.
[32] Galimand M, Carniel E, Courvalin P.Resistance of Yersin-iapestis to antimicrobial agents[J]. Antimicrob Agents Chem-other, 2006,50(10):3233-3236.
[33] Galimand M, Guiyoule A, Gerbaud G, et al.Multidrug resisted by a transferable plasmid[J]. N Engl J Med, 1997,337(10):677-680.
[34] 黎海舰, 岑志陟, 陆绍强, 等. 广西暴发流行人间鼠疫42例报告[J]. 中国人兽共患病学报, 2002, 18(5):111-111.
[35] Louie A, Deziel M R, Liu W, et al.Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague Therapy[J]. Antimi-crobial Agents and Chemotherapy, 2007,51(8):2661-2667.
[36] Hernandez E, Girardet M, Ramisse F, et al.Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimic-robial agents[J]. The Journal of antimicrobial chemotherapy, 2003,52(6):1029-1031.
[37] Frean J A, Arntzen L, Capper T, et al.In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus[J]. Antimicrobial Agents and Chemotherapy, 1996,40(11):2646-2647.
[38] 崔百忠, 王祖郧, 王虎. 治疗鼠疫药物的筛选[J]. 中国人兽共患病学报, 2009,25(8):827-829.
[39] 王国钧, 李敏, 李海龙, 等. 头孢曲松治疗大白兔实验感染鼠疫疗效观察[J]. 中国地方病学杂志, 2006, 25(5):500-502.
[40] Louie A, VanScoy B, Liu W, et al. Comparative Efficacies of Candidate Antibiotics against Yersinia pestis in an In Vitro Pharmacodynamic Model[J]. Antimicrobial Agents and Chemotherapy, 2011,55(6):2623-2628.
[41] 肖永红, 喻玮. 积极行动,控制碳青霉烯类耐药肠杆菌流行刻不容缓！[J]. 中华临床感染病杂志, 2017, 10(6):401-407.
[42] 王其琼, 张舒, 封宇飞, 等. 新型治疗复杂性尿路感染药物-plazomicin[J]. 临床药物治疗杂志, 2019,17(6):6-10.
[43] Mega W M, Doyle-Eisele M, Cass R T, et al.Plazomicin is effective in a non-human primate pneumonic plague model[J]. Bioorganic & Medicinal Chemistry, 2016,24(24):6429-6439.
[44] Gur D, Glinert I, Aftalion M, et al.Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model[J].Front Microbiol. 2018;9:741. doi:10.3389/fmicb. 2018.00741.
[45] Levy Y, Vagima Y, Tidhar A, et al.Adjunctive Corticosteroid Treatment Against Yersinia pestis Improves Bact-erial Clearance, Immun-opathology, and Survival in the Mouse Model of Bubonic Plague[J]. J Infect Dis, 2016,214(6):970-977. [46]罗阳燕, 李荣山, 乔玉峰, 等. 三氟拉嗪对人肾小球系膜细胞增殖和周期的影响[J]. 国际移植与血液净化杂志, 2014,12(4):38-41.
[47] Andersson J A, Fitts E C, Kirtley M L, et al.New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria[J]. Antimicrobial agents and chemotherapy,2016, 60(6):3717-3729.